- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 23.12.25 | RACURA ONCOLOGY LTD: Racura Oncology Appoints BDD for HARNESS-1 Trial | - | ASX | ||
| 23.12.25 | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 18.12.25 | RACURA ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | - | ASX | ||
| 18.12.25 | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 3 | ASX | ||
| 17.12.25 | Inside Racura Oncology: Strategy, clinical milestones, and the year ahead | 1 | The Market Herald Australia | ||
| RACURA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 11.12.25 | Long Shortz with Racura: Inside the $3.22M raise powering a lung cancer trial | 1 | Stockhead | ||
| 11.12.25 | RACURA ONCOLOGY LTD: Cleansing Notice | - | ASX | ||
| 11.12.25 | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | - | ASX | ||
| 11.12.25 | RACURA ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 09.12.25 | RACE ONCOLOGY LTD: Change of Company Name | 1 | ASX | ||
| 09.12.25 | Race Oncology's placement-at-a-premium rewarded as shares jump +8% | 4 | The Market Herald Australia | ||
| 09.12.25 | Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher | 32 | The Motley Fool Australia | ||
| 08.12.25 | RACE ONCOLOGY LTD: Proposed issue of securities - RAC | - | ASX | ||
| 08.12.25 | RACE ONCOLOGY LTD: Race Oncology Completes $3.22m Private Placement | - | ASX | ||
| 04.12.25 | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 28.11.25 | RACE ONCOLOGY LTD: Appendix 3Y -Dr Peter Smith | 4 | ASX | ||
| 28.11.25 | RACE ONCOLOGY LTD: Appendix 3Y - Dr Daniel Tillett | 1 | ASX | ||
| 27.11.25 | RACE ONCOLOGY LTD: Application for quotation of securities - RAC | 1 | ASX | ||
| 27.11.25 | RACE ONCOLOGY LTD: Race Oncology AGM 2025 Recording Released | - | ASX |
1 2 3 4 5 Weiter >>
81 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,06 | -0,05 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,250 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,47 | 0,00 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | ||
| ZENAS BIOPHARMA | 16,720 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) | - Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 62,80 | 0,00 % | Structure Therapeutics stock gets BMO Capital's Outperform rating reaffirmed | ||
| HARMONY BIOSCIENCES | 36,750 | 0,00 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 72,37 | 0,00 % | KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? | ||
| QIAGEN | 39,525 | +1,69 % | QIAGEN NV - Stabilität als strategische Zone | ||
| VERA THERAPEUTICS | 47,080 | 0,00 % | Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46%... ► Artikel lesen | |
| NUVALENT | 97,82 | 0,00 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| MINERALYS THERAPEUTICS | 35,580 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| TREVI THERAPEUTICS | 11,360 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 30,210 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,230 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
RACURA ONCOLOGY LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,010 (+0,67 %) liegt der Kurs bei 1,510 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RACURA ONCOLOGY LTD finden Sie auf Wallstreet Online.